Senescent glioblastoma cells arising after radiotherapy secrete tumor-promoting factors that engender the senescence-associated secretory phenotype (SASP). SASP factors secreted by senescent cells ...

Among patients with recurrent high-grade glioma, investigators found that fractionated reirradiation ... it was given at 75 milligrams per square meter (mg/m 2) daily, whereas Avastin (bevacizumab) ...

Jason Mollring, 52, who had a clean bill of health, has been given 12 to 18 months to live after being diagnosed with glioblastoma – an incurable form of brain cancer. Last April, he suffered a ...

The most commonly used systemic agents in recurrent gliomas are: bevacizumab, nitrosoureas, and temozolomide rechallenge. In this setting, bevacizumab plays a crucial role. It is a targeted therapy ...

Targeted therapies offer a more precise approach to treating gliomas by focusing on specific genetic mutations or pathways involved in tumor growth. Some options include: Bevacizumab (Avastin): A ...

TPI 287 has been well tolerated in over 350 patients to date, including in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of recurrent glioblastoma ...

Our group is primarily focused on high grade gliomas which arise in children, either supratentorially, or within the brainstem. High-grade gliomas in children share similar histopathological features ...

Purpose: The management of recurrent WHO grades II–III (rGII–III) glioma is not well established. This study describes the clinical outcomes in patients who received bevacizumab as rescue treatment.